Pharmacodynamic Mechanisms of the Development of Pulmonary Fibrosis Due to Amiodarone use
Main Article Content
Abstract
Introduction: Amiodarone is a benzofuran derivative with highly effective class III antidysrhythmic activity used in ventricular and supraventricular arrhythmia; however, its most side effect is pulmonary toxicity, with an incidence of 0 to 10%, and a mortality of 1 to 33%. The mechanism of the adverse reaction is still a matter of investigation. Therefore, the overall objective of this study is to determine the time in which pulmonary fibrosis develops from the use of amiodarone, which we hope to obtain with the following research question: What is the time in which pulmonary fibrosis develops from the use of amiodarone?
Discussion: based on the sources reviewed, these establish that there is a risk of developing pulmonary adverse reactions from the therapeutic use of amiodarone directly related to the serum concentrations of the drug, but complete these data with broader populations.
Conclusions: We were able to determine from the literature review that lung injury can be activated by low and high therapeutic doses of amiodarone.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Katzung, B.: antiarrítmicos. Mc Graw Hill LANGE, Farmacología básica y clínica, 12a edición MÉXICO DF o Santa Fe de Bogotá, 2013, 227-250.
II. Goodman & Gilman, antiarrítmicos, Mac Graw Hill, LAS BASES FARMACOLÓGICAS DE LA TERAPÉUTICA, 12 edición, 2015, 816-848.
III. Harrison, Interamericana, Enfermedades pulmonares intersticiales, McGraw-Hill, Harrison Principios de Medicina Interna, 19 edición, 2016, 2160-2194.
IV. Bader Al-Shammari, Hindawi Publishing corporation, oxidative medicine and cellular longevity, A mechanistic study on the amiodarone-induced pulmonary toxicity, Volumen 16.
V. Flippo Benassi,ECMo for pulmonary rescue in an adult with amiodarone-induced toxicity, Heart Vessels, 2015.
VI. Heiko Baumann, Rapid onset of amiodarone induced pulmonary toxicity after lung lobe resection - A case report and review of recent literature. Elsevier, annals of medicine and surgery. 21 (2017) 53e57
VII. Alexander J. Sweidan, Amiodarone-induced pulmonary toxicity, a frequently missed complication, libertas academica, 2016.
VIII. J. Mankikian, Initial characteristics and outcome of hospitalized patients with amiodarone pulmonay toxicity, Respiratory medicine, Elservier, 2014
IX. Hamilton, D., Nandkeolyar, S., Lan, H. et al. Amiodarone: A Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs 20, 549–558 (2020). https://doi.org/10.1007/s40256-020-00401-5.
X. Sgalla, G., Iovene, B., Calvello, M. et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res 19, 32 (2018). https://doi.org/10.1186/s12931-018-0730-2
XI. Ganesh, Raghu. (2022). Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults. American Journal of Respiratory and Critical Care Medicine, (Volume 205 Number 9), 18-47
XII. El Tabaa, M.M., El Tabaa, M.M., Elgharabawy, R.M. et al. Suppressing NLRP3 activation and PI3K/AKT/mTOR signaling ameliorates amiodarone-induced pulmonary fibrosis in rats: a possible protective role of nobiletin. Inflammopharmacol 31, 1373–1386 (2023). https://doi.org/10.1007/s10787-023-01168-2
XIII. Strykowski, Rachel . (2023). Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. Immunology and Allergy Clinics of North America, (43), 209-228.